DDInter103 DDInter1376
Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression. Although the exact mechanism of action is unknown, equine anti-thymocyte globulin targets a variety of immune system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and other cell types. Equine ATG is currently indicated for the suppression of the immune system to prevent renal transplant rejection and in the treatment of aplastic anemia. Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Antilymphocyte immunoglobulin (horse) {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Antilymphocyte immunoglobulin (horse) {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Antilymphocyte immunoglobulin (horse) {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Antilymphocyte immunoglobulin (horse) {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Antilymphocyte immunoglobulin (horse) {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Antilymphocyte immunoglobulin (horse) may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Cladribine